- Home
- COLL vs PHVS Comparison
COLL vs PHVS Comparison
Compare COLL & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COLL
- PHVS
- Stock Information
- Founded
- COLL 2002
- PHVS 2015
- Country
- COLL United States
- PHVS Switzerland
- Employees
- COLL N/A
- PHVS N/A
- Industry
- COLL Biotechnology: Pharmaceutical Preparations
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- COLL Health Care
- PHVS Health Care
- Exchange
- COLL Nasdaq
- PHVS Nasdaq
- Market Cap
- COLL 958.8M
- PHVS 980.3M
- IPO Year
- COLL 2015
- PHVS 2021
- Fundamental
- Price
- COLL $30.35
- PHVS $18.60
- Analyst Decision
- COLL Strong Buy
- PHVS Buy
- Analyst Count
- COLL 4
- PHVS 6
- Target Price
- COLL $43.75
- PHVS $37.17
- AVG Volume (30 Days)
- COLL 283.6K
- PHVS 35.3K
- Earning Date
- COLL 08-07-2025
- PHVS 08-13-2025
- Dividend Yield
- COLL N/A
- PHVS N/A
- EPS Growth
- COLL N/A
- PHVS N/A
- EPS
- COLL 1.25
- PHVS N/A
- Revenue
- COLL $664,283,000.00
- PHVS N/A
- Revenue This Year
- COLL $20.04
- PHVS N/A
- Revenue Next Year
- COLL $3.98
- PHVS N/A
- P/E Ratio
- COLL $24.19
- PHVS N/A
- Revenue Growth
- COLL 17.17
- PHVS N/A
- 52 Week Low
- COLL $23.23
- PHVS $11.51
- 52 Week High
- COLL $42.29
- PHVS $25.50
- Technical
- Relative Strength Index (RSI)
- COLL 54.25
- PHVS 60.00
- Support Level
- COLL $29.28
- PHVS $16.72
- Resistance Level
- COLL $30.83
- PHVS $17.53
- Average True Range (ATR)
- COLL 0.75
- PHVS 0.92
- MACD
- COLL -0.00
- PHVS 0.07
- Stochastic Oscillator
- COLL 51.63
- PHVS 94.55
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.